TNFRSF9 and neoplasm: In addition, combined anti-TIM-3/CD137 mAbs were even more efficacious in 3 days established ID8 tumor model with 100% of mice remaining free of tumor 90 days post-injection (Figure 1A; p < 0.001 compared to control mAb).